The global celiac disease diagnostics market is poised for significant growth, projected to reach a value of US$ 647.3 million by 2033, with a Compound Annual Growth Rate (CAGR) of 8.3%. This forecast marks a substantial increase from its net worth of almost US$ 292.8 million in 2023.
Celiac disease, an autoimmune disorder triggered by the ingestion of gluten, affects millions worldwide. As awareness of this condition grows and its prevalence rises, there’s an increasing demand for advanced diagnostic solutions. Technological advancements in diagnostic tests further propel market expansion, enabling more accurate and timely detection of celiac disease.
Request A Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-17187
Individuals with celiac disease experience adverse reactions to gluten, a protein found in wheat, rye, and barley. When gluten is consumed, the body’s immune system mistakenly attacks the small intestine lining, leading to various symptoms including bloating, diarrhea, weight loss, and abdominal pain. Left untreated, celiac disease can result in severe complications such as malnutrition and an elevated risk of developing certain cancers.
The escalating prevalence of celiac disease underscores the urgent need for improved diagnostic capabilities. The global market for celiac disease diagnostics is positioned to address this demand, offering innovative solutions to facilitate early detection and management of the condition.
Key Takeaways:
- North America is expected to remain the largest market for celiac disease diagnostics throughout the forecast period.
- The celiac disease serology tests segment is expected to account for the largest share of the market in 2023, but the molecular diagnostics segment is expected to grow at the fastest CAGR during the forecast period.
- The rising demand for non-invasive and point-of-care diagnostic tests is expected to boost the growth of the celiac disease diagnostics market in the coming years.
Factors driving the growth of the celiac disease diagnostics market:
- Increasing awareness of celiac disease: Celiac disease is a chronic autoimmune disorder that causes damage to the small intestine when gluten is consumed. Gluten is a protein found in wheat, rye, and barley. While celiac disease has been known for centuries, awareness of the disease has increased significantly in recent years. This is due in part to public awareness campaigns by celiac disease organizations as well as the increasing availability of gluten-free foods.
- Rising prevalence of celiac disease: The prevalence of celiac disease is estimated to be around 1% of the global population. However, some studies suggest that the prevalence may be even higher. This is likely due to a number of factors, including genetic predisposition, environmental triggers, and the increased consumption of gluten-containing foods.
- Increasing availability of diagnostic tests: There are a number of diagnostic tests available for celiac disease. The most common test is a blood test that looks for antibodies to gluten. If the blood test is positive, a biopsy of the small intestine may be performed to confirm the diagnosis. In recent years, there has been an increasing development of non-invasive diagnostic tests, such as genetic testing and stool testing. These tests are still under development, but they have the potential to make the diagnosis of celiac disease easier and more accessible.
Click for Methodology Details: https://www.futuremarketinsights.com/request-report-methodology/rep-gb-17187
Key Companies Profiled:
- Thermo Fisher Scientific Inc.
- PRIMA Lab SA
- Glutenostics, Inc.
- NanoRepro AG.
- Targeted Genomics
- YORKTEST Laboratories
- Biohit Oyj
- Labsystems Diagnostics Oy
- RxHome Test
- Biomerica
- AESKU.GROUP GmbH
- LaCAR MDx Technologies
- J. Mitra & Co. Pvt. Ltd.
- Imaware
- Vitrosens Biotechnology
- Bio-Rad Laboratories Inc.
- Eurofins Scientific
Key Segments Covered in Celiac Disease Diagnostics Industry Research:
By Product Type:
- Serology Rapid Testing Kits
- Transglutaminase Antibody Test Kits
- Endomysial Antibody Test Kits
- Anti-Giladin Antibody Test Kits
- Genetic Rapid Testing Kits
By Technique:
- Immunochromatography (Lateral Flow)
- enzyme-linked immunosorbent assay (ELISA)
By Sample:
- Blood Serum
- Body Fluids
By End User:
- Hospitals
- Diagnostic Laboratories
- Specialty Clinics
- Home Care Setting
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa (MEA)
Direct Purchase of this Report: https://www.futuremarketinsights.com/checkout/17187
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
